LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 187

Search options

  1. Book ; Online: Critical Issues in Head and Neck Oncology

    Vermorken, Jan B. / Budach, Volker / Leemans, C. René / Machiels, Jean-Pascal / Nicolai, Piero / O'Sullivan, Brian

    Key Concepts from the Eighth THNO Meeting

    2023  

    Author's details edited by Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O'Sullivan
    Keywords Oncology ; Radiology ; Cancer—Treatment
    Subject code 616.994
    Language English
    Size 1 Online-Ressource (IX, 365 p. 65 illus., 58 illus. in color)
    Edition 1st ed. 2023
    Publisher Springer International Publishing ; Imprint: Springer
    Publishing place Cham
    Document type Book ; Online
    HBZ-ID HT021862802
    ISBN 978-3-031-23175-9 ; 9783031231742 ; 9783031231766 ; 9783031231773 ; 3-031-23175-9 ; 3031231740 ; 3031231767 ; 3031231775
    DOI 10.1007/978-3-031-23175-9
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Book ; Online: Critical Issues in Head and Neck Oncology

    Vermorken, Jan B / Budach, Volker / Leemans, C. René / Machiels, Jean-Pascal / Nicolai, Piero / O'Sullivan, Brian

    Key Concepts from the Eighth THNO Meeting

    2023  

    Keywords Oncology ; Radiology ; Head and Neck Cancer ; Predictive markers ; Non-orophayngeal head and neck cancer ; Induction chemotherapy ; Radiation Oncology ; Surgical Oncology ; Liquid biopsies ; Precision medicine ; HNSCC ; Nasopharynx cancer ; Immunotherapy ; Personalized Medicine
    Language English
    Size 1 electronic resource (365 pages)
    Publisher Springer Nature
    Publishing place Cham
    Document type Book ; Online
    Note English
    HBZ-ID HT030374720
    ISBN 9783031231742 ; 3031231740
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  3. Book ; Online: Critical Issues in Head and Neck Oncology

    Vermorken, Jan B. / Budach, Volker / Leemans, C. René / Machiels, Jean-Pascal / Nicolai, Piero / O’Sullivan, Brian

    Key Concepts from the Seventh THNO Meeting

    2021  

    Author's details edited by Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O’Sullivan
    Keywords Oncology   ; Radiotherapy ; Surgical oncology
    Subject code 616.994
    Language English
    Size 1 Online-Ressource (IX, 373 p. 39 illus., 33 illus. in color)
    Edition 1st ed. 2021
    Publisher Springer International Publishing ; Imprint: Springer
    Publishing place Cham
    Document type Book ; Online
    HBZ-ID HT020977441
    ISBN 978-3-030-63234-2 ; 9783030632335 ; 9783030632359 ; 9783030632366 ; 3-030-63234-2 ; 3030632334 ; 3030632350 ; 3030632369
    DOI 10.1007/978-3-030-63234-2
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  4. Book ; Online: Critical Issues in Head and Neck Oncology : Key Concepts from the Seventh THNO Meeting

    Vermorken, Jan B. / Budach, Volker / Leemans, C. René / Machiels, Jean-Pascal / Nicolai, Piero / O'Sullivan, Brian

    2021  

    Keywords Oncology ; Radiotherapy ; Surgical oncology ; Surgical Oncology ; Internal Medicine ; Radiology ; Surgery ; Nasopharynx cancer ; Head and Neck Squamous Cell Cancer ; non-oropharyngeal head and neck cancer ; predictive biomarkers ; liquid biopsies ; induction chemotherapy ; immunotherapy ; precision medicine ; HNSCC ; Open Access
    Size 1 electronic resource (373 pages)
    Publisher Springer Nature
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021051330
    ISBN 9783030632342 ; 3030632342
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  5. Book ; Online ; Conference proceedings ; E-Book: Critical issues in head and neck oncology

    O'Sullivan, Brian / Vermorken, Jan B. / Budach, Volker / Leemans, C. René / Machiels, Jean-Pascal / Nicolai, Pietro

    key concepts from the Fifth THNO Meeting

    2017  

    Event/congress Trends in Head and Neck Oncology (5., 2015, Lissabon)
    Author's details editors Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O'Sullivan
    Keywords Head and Neck Neoplasms / diagnosis ; Head and Neck Neoplasms / therapy ; Clinical Decision-Making ; Europe / https://id.nlm.nih.gov/mesh/D005060
    Language English
    Size 1 Online-Ressource (xiii, 296 Seiten), Illustrationen
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; Conference proceedings ; E-Book
    Note Tagungsdaten: 05 Nov - 07 Nov 2015, Lisbon, Portugal
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019470438
    ISBN 978-3-319-42909-0 ; 9783319429076 ; 3-319-42909-4 ; 3319429078
    DOI 10.1007/978-3-319-42909-0
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  6. Article ; Online: Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN).

    Galot, Rachel / Machiels, Jean-Pascal H

    Cancer treatment reviews

    2020  Volume 85, Page(s) 101992

    Abstract: Liquid biopsies (LB) are emerging in the oncology field, with promising data as new diagnostic, prognostic and treatment-monitoring tools. Squamous cell carcinoma of the head and neck (SCCHN) is a heterogenous disease and many challenges remain to ... ...

    Abstract Liquid biopsies (LB) are emerging in the oncology field, with promising data as new diagnostic, prognostic and treatment-monitoring tools. Squamous cell carcinoma of the head and neck (SCCHN) is a heterogenous disease and many challenges remain to improve patient outcomes. Liquid biopsy could be of interest at different stages of SCCHN disease, including better screening to diagnose more patients at an early stage, early detection of relapse after curative treatment, and the implementation of precision medicine. As LB is very attractive by the ease of sampling, this field is moving fast. Therefore, it is important to be aware of the potential applications but also the limitations of these new tools in regards to technical aspects and interpretation of the data. In this review, we will first give an overview of potential clinical applications and technical challenges of circulating tumor DNA (ctDNA) and then focus on current available data of ctDNA in SCCHN. Although the literature on ctDNA analysis for SCCHN is scarce compared to other tumors, preliminary results seem to hold promise for the future, including the detection of minimal residual disease or the detection of potentially targetable events through liquid biopsy. Prospective liquid-biopsy driven clinical trials are needed to validate its clinical relevance.
    MeSH term(s) Biomarkers, Tumor/genetics ; Biopsy, Needle ; Circulating Tumor DNA/blood ; Female ; Head and Neck Neoplasms/genetics ; Head and Neck Neoplasms/pathology ; Humans ; Immunohistochemistry ; Male ; Monitoring, Physiologic/methods ; Neoplasm Invasiveness/pathology ; Neoplasm Staging ; Prognosis ; Sensitivity and Specificity ; Squamous Cell Carcinoma of Head and Neck/genetics ; Squamous Cell Carcinoma of Head and Neck/pathology
    Chemical Substances Biomarkers, Tumor ; Circulating Tumor DNA
    Language English
    Publishing date 2020-02-14
    Publishing country Netherlands
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 125102-8
    ISSN 1532-1967 ; 0305-7372
    ISSN (online) 1532-1967
    ISSN 0305-7372
    DOI 10.1016/j.ctrv.2020.101992
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Vaccine-Based Immunotherapy for Head and Neck Cancers.

    Beyaert, Simon / Machiels, Jean-Pascal / Schmitz, Sandra

    Cancers

    2021  Volume 13, Issue 23

    Abstract: In 2019, the FDA approved pembrolizumab, a monoclonal antibody targeting PD-1, for the first-line treatment of recurrent or metastatic head and neck cancers, despite only a limited number of patients benefiting from the treatment. Promising effects of ... ...

    Abstract In 2019, the FDA approved pembrolizumab, a monoclonal antibody targeting PD-1, for the first-line treatment of recurrent or metastatic head and neck cancers, despite only a limited number of patients benefiting from the treatment. Promising effects of therapeutic vaccination led the FDA to approve the use of the first therapeutic vaccine in prostate cancer in 2010. Research in the field of therapeutic vaccination, including possible synergistic effects with anti-PD(L)1 treatments, is evolving each year, and many vaccines are in pre-clinical and clinical studies. The aim of this review article is to discuss vaccines as a new therapeutic strategy, particularly in the field of head and neck cancers. Different vaccination technologies are discussed, as well as the results of the first clinical trials in HPV-positive, HPV-negative, and EBV-induced head and neck cancers.
    Language English
    Publishing date 2021-11-30
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13236041
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group.

    Klinghammer, Konrad / Lorini, Luigi / Nevens, Daan / Simon, Christian / Machiels, Jean-Pascal / Bossi, Paolo

    Frontiers in oncology

    2022  Volume 12, Page(s) 730785

    Abstract: Multiple factors differentially influence treatment decisions in the first line treatment of recurrent/metastatic HNSCC. The EORTC Young investigator group launched a survey among treating physicians to explore the main influencing factors for treatment ... ...

    Abstract Multiple factors differentially influence treatment decisions in the first line treatment of recurrent/metastatic HNSCC. The EORTC Young investigator group launched a survey among treating physicians to explore the main influencing factors for treatment stratification. The questionnaire was posted as a web-survey link from May to August 2020. Next to defining the factors that mostly influence therapeutic decision the survey was complemented by a clinical case discussion of five patient cases. A total of 118 responses from 19 countries were collected. The key factors identified to guide treatment decision were performance status, PD-L1 Expression, time from last systemic treatment above or below 6 months, and disease burden. Prospective evaluation of patient characteristics and additional potential predictive biomarkers for novel treatment options remains an important question to stratify personalized treatment for RM HNSCC.
    Language English
    Publishing date 2022-01-27
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.730785
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours.

    Schöffski, Patrick / Machiels, Jean-Pascal / Rottey, Sylvie / Sadrolhefazi, Behbood / Musa, Hanny / Marzin, Kristell / Awada, Ahmad

    European journal of cancer (Oxford, England : 1990)

    2023  Volume 191, Page(s) 112987

    Abstract: Background: Bromodomain and extraterminal domain (BET) inhibitors have demonstrated efficacy in solid tumours and haematological malignancies. BI 894999 is a novel oral BET inhibitor that has demonstrated potent antitumour activity in preclinical ... ...

    Abstract Background: Bromodomain and extraterminal domain (BET) inhibitors have demonstrated efficacy in solid tumours and haematological malignancies. BI 894999 is a novel oral BET inhibitor that has demonstrated potent antitumour activity in preclinical studies.
    Patients and methods: 1367.1 was an open-label, Phase Ia/Ib dose-finding study evaluating BI 894999 once daily in patients with advanced solid tumours (Schedule A: 0.2, 0.5, 1.0, 1.5, 2.0, and 5.0 mg, Days 1-21/21-d cycle; Schedule B: 1.5, 2.0, and 2.5 mg, Days 1-15/21-d cycle; Schedule C: loading dose 5.0, 6.0, or 7.0 mg on Day 1 followed by maintenance dose 2.5, 3.0, or 3.5 mg, Days 2-7 and 15-21/28-d cycle); 77 patients were enrolled. NCT02516553.
    Results: Grade ≥3 dose-limiting toxicities (DLTs) were reported in 8/21, 5/25, and 9/31 patients for Schedules A, B, and C, respectively. Thrombocytopenia was reported as a DLT in 28.6%, 4.8%, and 9.7% for Schedules A, B, and C, respectively. Other DLTs occurring in ≥1 patient were troponin T increase (13.6%), hypophosphataemia (4.5%), and elevated creatine phosphokinase (3.0%). Disease control was achieved in 23.8%, 24.0%, and 29.0% of patients for Schedules A, B, and C, respectively. A partial response was achieved in 9.5% and 4% of patients with Schedules A and B, respectively. The best response with Schedule C was stable disease.
    Conclusion: The 1.5, 2.5, and 6.0/3.0 mg doses in Schedules A, B, and C, respectively, were declared as maximum tolerated dose. Based on the strength of these data, BI 894999 was further evaluated in a Phase Ib trial.
    MeSH term(s) Humans ; Neoplasms/drug therapy ; Neoplasms/pathology ; Benzene Derivatives ; Maximum Tolerated Dose ; Dose-Response Relationship, Drug
    Chemical Substances BI 894999 ; Benzene Derivatives
    Language English
    Publishing date 2023-07-11
    Publishing country England
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2023.112987
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?

    Bossi, Paolo / Seront, Emmanuel / Machiels, Jean Pascal

    Oral oncology

    2019  Volume 94, Page(s) 121–122

    MeSH term(s) Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/radiotherapy ; Female ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/pathology ; Head and Neck Neoplasms/radiotherapy ; Humans ; Induction Chemotherapy/methods ; Male
    Language English
    Publishing date 2019-05-21
    Publishing country England
    Document type Letter
    ZDB-ID 1120465-5
    ISSN 1879-0593 ; 0964-1955 ; 1368-8375
    ISSN (online) 1879-0593
    ISSN 0964-1955 ; 1368-8375
    DOI 10.1016/j.oraloncology.2019.05.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top